stoxline Quote Chart Rank Option Currency Glossary
Aerie Pharmaceuticals, Inc. (AERI)
15.25  0 (0%)    11-18 16:00
Open: 15.24
High: 15.25
Volume: 1,215,184
Pre. Close: 15.25
Low: 15.24
Market Cap: 0(M)
Technical analysis
2022-12-09 4:20:13 PM
Short term     
Mid term     
Targets 6-month :  17.81 1-year :  20.8
Resists First :  15.25 Second :  17.81
Pivot price 15.23
Supports First :  15.2 Second :  15.17
MAs MA(5) :  15.24 MA(20) :  15.22
MA(100) :  12.91 MA(250) :  9.7
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  93.3 D(3) :  89.6
RSI RSI(14): 68.3
52-week High :  15.36 Low :  4.8
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ AERI ] has closed below upper band by 9.1%. Bollinger Bands are 97.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 49 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 15.29 - 15.36 15.36 - 15.42
Low: 15.03 - 15.13 15.13 - 15.22
Close: 15.1 - 15.26 15.26 - 15.39
Company Description

Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.

Headline News

Wed, 29 May 2024
Aerie Pharmaceuticals to Participate in Upcoming Investor Conferences - Quantisnow

Sun, 26 May 2024
Aerie (AERI) Up 1.9% Since Last Earnings Report: Can It Continue? - Yahoo New Zealand News

Thu, 23 May 2024
Heron Therapeutics (HRTX) in Focus: Stock Gains 7.5% - Yahoo Movies Canada

Sun, 12 May 2024
Aerie Pharmaceuticals (AERI) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Canada Shine On

Mon, 06 May 2024
Karyopharm Therapeutics (KPTI) Jumps: Stock Up 93.5% - Yahoo Canada Shine On

Tue, 22 Nov 2022
Alcon Completes Acquisition of Aerie Pharmaceuticals, Inc., Strengthening Company's Ophthalmic Pharmaceutical ... - Business Wire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Drug Manufacturers - Specialty & Generic
Shares Out 49 (M)
Shares Float 44 (M)
Held by Insiders 1.7 (%)
Held by Institutions 103 (%)
Shares Short 1,520 (K)
Shares Short P.Month 1,600 (K)
Stock Financials
EPS -1.48
EPS Est Next Qtrly -0.7
EPS Est This Year -2.59
EPS Est Next Year -2.18
Book Value (p.s.) -3.32
Profit Margin -17.1 %
Operating Margin -12.5 %
Return on Assets (ttm) -4.6 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 23.2 %
Gross Profit (p.s.) 3.38
Sales Per Share 4.32
EBITDA (p.s.) -0.14
Qtrly Earnings Growth 0 %
Operating Cash Flow 7 (M)
Levered Free Cash Flow 2 (M)
Stock Valuations
PE Ratio -10.38
PEG Ratio 0
Price to Book value -4.6
Price to Sales 3.52
Price to Cash Flow 105.11
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android